Back to top
more

Bayer (BAYRY)

(Delayed Data from OTC)

$7.60 USD

7.60
2,551,609

0.00 (0.00%)

Updated May 3, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 23% (194 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: AZN, ABBV Mixed Q4 Results, BAYRY's New CEO

by Kinjel Shah

AstraZeneca (AZN) and AbbVie (ABBV) report fourth-quarter results. Roche (RHHBY) and J&J (JNJ) announce positive data from studies on pipeline candidates for rare diseases.

Regeneron's (REGN) Eylea Gets FDA Nod for ROP in Infants

by Zacks Equity Research

Regeneron's (REGN) Eylea gets FDA approval for the treatment of preterm infants with retinopathy of prematurity (ROP).

Will Biogen (BIIB) Beat Estimates This Earnings Season?

by Zacks Equity Research

Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.

AstraZeneca (AZN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.

AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

AbbVie's (ABBV) Q4 performance will likely reflect strong drug demand from its immunology and neuroscience franchises. Investors will also enquire about ABBV's plans to counter Humira LOE.

Regeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

BAYRY or LLY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BAYRY vs. LLY: Which Stock Is the Better Value Option?

Regeneron (REGN) Down on Ophthalmology Drug Eylea Sales Update

by Zacks Equity Research

Regeneron's (REGN) lead drug Eylea's sales decline in the fourth quarter due to a short-term shift to off-label use of Avastin.

What's in Store for Regeneron Pharmaceuticals (REGN) in 2023?

by Zacks Equity Research

Regeneron Pharmaceuticals (REGN) had a good run in 2022 and the momentum should continue in 2023 on the back of growth in Eylea and Dupixent.

The Zacks Analyst Blog Highlights Visa, Texas Instruments, EOG, Bayer Aktiengesellschaft and Aflac

by Zacks Equity Research

Visa, Texas Instruments, EOG, Bayer Aktiengesellschaft and Aflac are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Visa, Texas Instruments & EOG Resources

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Texas Instruments Incorporated (TXN) and EOG Resources, Inc. (EOG).

Regeneron (REGN) Presents Positive Data on MM and FL Drugs

by Zacks Equity Research

Regeneron (REGN) releases positive initial data on two candidates - linvoseltamab and odronextamab at ASH.

Regeneron (REGN) Outperforms YTD: What's in Store for 2023?

by Zacks Equity Research

Regeneron (REGN) has had a good run in 2022 so far and the momentum should continue in 2023 as well.

Why Bayer Aktiengesellschaft (BAYRY) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

BAYRY vs. NVO: Which Stock Is the Better Value Option?

by Zacks Equity Research

BAYRY vs. NVO: Which Stock Is the Better Value Option?

Eli Lilly (LLY) Stock Up 26.7% YTD: What's in Store for 2023?

by Zacks Equity Research

Lilly (LLY) expects to launch five new medicines by 2023-end, including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.

AstraZeneca's (AZN) Imfinzi/Imjudo Combo Gets Another FDA Nod

by Zacks Equity Research

AstraZeneca (AZN) gets its second FDA approval for the Imfinzi+Imjudo combo in non-small cell lung cancer (NSCLC) indication.

Bayer (BAYRY) Eylea Label Extension Gets CHMP Positive Opinion

by Zacks Equity Research

Bayer (BAYRY) gets positive recommendation from the CHMP for label extension of ophthalmology drug Eylea for the treatment of preterm infants with retinopathy of prematurity.

Sanofi (SNY), Regeneron Dupixent Gets CHMP Nod for Skin Disease

by Zacks Equity Research

The CHMP recommends approval of Sanofi's (SNY) Dupixent for the treatment of prurigo nodularis, a chronic inflammatory skin disease.

Kinjel Shah headshot

Pharma Stock Roundup: Q3 Earnings of BAYRY, AZN, EU Nod for AZN, SNY RSV Vaccine

by Kinjel Shah

Bayer (BAYRY) and AstraZeneca (AZN) announce third-quarter results. AstraZeneca and Sanofi's (SNY) RSV vaccine, nirsevimab gets approval in Europe.

Kodiak Sciences' (KOD) Q3 Earnings Beat, Eye Candidate in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports a narrower-than-expected loss for the third quarter of 2022. The focus is on the lead candidate, KSI-301, developed for treating various retinal vascular diseases.

AstraZeneca's (AZN) Q3 Earnings Beat, EPS Growth View Up

by Zacks Equity Research

AstraZeneca (AZN) beats third-quarter estimates for earnings while sales come in line. AZN raises its 2022 earnings growth guidance, keeping its sales forecast unchanged.

Bayer's (BAYRY) Q3 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research

Bayer's (BAYRY) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.

Ginkgo (DNA) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Ginkgo's (DNA) third-quarter earnings call, investor focus is likely to be on the company's progress with its collaboration deals and the performance of its business units.